Midyear 2025 podcast ideas updates

Episode Summary

Executive Summary: Andrew Walker revisits his 2025 solo stock ideas on Sage Therapeutics, Keros, and Full House Resorts. Sage is being acquired, validating his sell-the-company thesis and possibly inviting a topping bid from Biogen. Keros has returned capital and faces pressure for more. Full House is mixed: American Place is outperforming while Cripple Creek lags, but insider buying and refinancing progress support his bullish long-term view.

Main Topics: Sage Therapeutics acquisition and thesis validation (Priority: 5/5): Walker argues Sage should have sold because its value lay in cash plus the Biogen-linked Zerzuve asset. He says the agreed sale at $8.50/share plus CVR is compelling, but still thinks Biogen may top the bid because it is the natural strategic buyer and the current deal implies a very low enterprise value. Shareholder pressure and activist engagement (Priority: 5/5): He emphasizes that shareholder letters, podcast commentary, and public pressure helped push Sage toward a sale and likely influenced Keros's capital return. He frames engaged shareholders as capable of forcing boards to act in shareholders' interests. Keros strategic alternatives and capital return (Priority: 4/5): Keros has announced strategic alternatives and a $375 million capital return, which Walker views as a good start but insufficient given excess cash and high burn. He argues more capital should be returned and that management should reduce cash burn and stop operating with an oversized balance sheet. Full House Resorts: mixed operating progress (Priority: 5/5): Walker says his top 2025 idea is down year-to-date, but the underlying business is progressing. American Place is exceeding expectations and the nuisance litigation risk is gone, while Cripple Creek's Chamonix ramp has been slower than expected and management change was needed. Insider buying as a bullish signal at Full House (Priority: 4/5): He highlights significant purchases by director Eric Green and CEO Dan Lee, especially Lee's large buy from his ex-wife at a substantial premium, as strong evidence insiders see much higher value ahead and believe refinancing risk will be resolved. Refinancing and dilution risk at Full House (Priority: 4/5): Walker says the main remaining uncertainty is refinancing a large debt package for American Place, but expects no equity dilution. He believes the refinancing will remove a major overhang and unlock upside as construction and ramp-up continue.

Key Arguments: Sage should no longer have remained public because the value of its cash and Zerzuve-linked asset exceeded the standalone stock price. Biogen is the only logical strategic buyer for Sage because it can capture JV synergies; if it does not bid higher, either it is undervaluing its own drug or it is a poor acquirer. The Sage process shows how shareholder pressure and open letters can materially affect board behavior and transaction outcomes. Keros had too much cash relative to its remaining pipeline and should return even more capital while lowering burn. Keros board election results showed investor dissatisfaction and likely helped force the capital return announcement. Full House's American Place project is the key value driver and is performing very well, with record months and reduced legal tail risk. Chamonix in Cripple Creek is underperforming versus expectations, but the project still may create a high-multiple asset over time. Large insider purchases at Full House, especially the CEO's, are interpreted as a strong signal that management believes the stock is materially undervalued. A successful refinancing at Full House without equity dilution should remove a major risk and could re-rate the stock higher. Walker believes the back half of 2025 and 2026-2027 should prove the Full House thesis right even if the stock has lagged so far.

Data Points: Sage acquisition price: $8.50/share plus CVR - Announced sale of Sage Therapeutics to Supernus Sage cash on balance sheet (Q1 2025): $424 million - Used to argue Sage enterprise value is very low after subtracting cash Sage equity value at deal price: $561 million - Cash portion of the acquisition consideration Implied Sage enterprise value: < $200 million - Walker estimates EV after adjusting for cash Potential royalty financing value for Sage lead drug: $200 million - Walker notes Sage had a royalty deal allowing borrowing against the lead drug Keros cash and equivalents (Q1 2025): $720 million - Used to argue Keros held excessive cash Keros capital return: $375 million - Announced as part of strategic alternatives conclusion Full House stock performance YTD: ~down 10% - Walker says the stock has lagged in 2025 Peer performance: Penn: ~down 10% - Gaming sector comparison Peer performance: Caesars: ~down 15% - Gaming sector comparison Peer performance: Boyd: ~up 7-8% - Gaming sector comparison Peer performance: MGM: ~flat - Gaming sector comparison American Place total investment: ~$500 million all-in - Walker estimates temporary plus permanent buildout costs American Place expected EBITDA: ~$100 million - Walker’s estimate of mature project economics American Place temporary opening investment: ~$200 million - Cost to open the temporary tent casino Chamonix target EBITDA: $50 million (aspirational) - Walker says his preferred near-term expectation is lower, around $25 million Chamonix near-term revised expectation: ~$25 million EBITDA - Walker’s updated view due to slower ramp Full House CEO insider buy: 270,000+ shares at $4.75/share - Dan Lee's large purchase on June 13 Full House CEO purchase premium: >50% premium to prior day's close - Walker emphasizes the buy was executed well above market Director purchase: 25,000 shares at $3.40/share - Eric Green's open-market buy in mid-May Director cash compensation: $62,000 per year - Used to show the size of the director buy relative to pay Refinancing bonus for CEO: $300,000 - Dan Lee’s contract includes a bonus for refinancing principal debt by March 30, 2027

Pivotal Quotes: "winner-winner chicken dinner" — Andrew Walker: His reaction to Sage Therapeutics agreeing to be acquired "the dog that's in bark" — Andrew Walker: His description of Biogen as the logical buyer who has not yet topped the Sage bid "Insiders buy for only one reason. They think the price will rise" — Andrew Walker: He uses this to frame the bullish meaning of Full House insider purchases

Implications: Listeners should expect continued corporate actions at Sage and Keros, while Full House remains a longer-dated special situation with execution and refinancing as the key swing factors. The episode reinforces that shareholder pressure and insider behavior can materially shape outcomes.